# TRIDENT-1 (NCT03093116)

> A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03093116
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Turning Point Therapeutics, Inc.
- Conditions: Locally Advanced Solid Tumors; Metastatic Solid Tumors
- Interventions: Oral repotrectinib (TPX-0005)
- Enrollment: 500
- Primary outcome: Dose limiting toxicities (DLTs) (Phase 1)
- Primary outcome: Recommended Phase 2 Dose (RP2D) (Phase 1)
- Primary outcome: Overall Response Rate (ORR) Phase 2

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 28
- Podcasts: 22
- YouTube: 14

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=trident-1-nct03093116

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03093116", "email": "<work email>"}; the inbox owner confirms by the emailed link.